Clinical Trial News
This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.
Get news By email or subscribe to our News feeds.
Posted Yesterday in Clinical Trials
?? The complete regulatory
toxicology package of GFT505 confirms its safety in long-term
treatment.
?
Lille (France), Cambridge
(Massachusetts, United States), February 8th, 2012 – GENFIT
(Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company
at the forefront of drug discovery and development, focusing on the
early diagnosis and preventive treatment of cardiometabolic...
Read more...Halting Bone-Building Osteoporosis Drug Use Cuts Risk for Additional Atypical Femur Fracture in Half
Posted Yesterday in Clinical Trials
SAN FRANCISCO, Feb. 8, 2012 /PRNewswire-USNewswire/ -- There is
growing evidence that supports an association between atypical
fractures of the femur – a rare break of the thigh bone,
typically without trauma – and the use of bisphosphonates,
drugs proven to enhance bone density and reduce fracture incidence
caused by osteoporosis. While the risk for suffering an atypical
femur fracture...
Read more... Posted Yesterday in Clinical Trials
Phase 3 Studies of Eliglustat Tartrate Fully Enrolled
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 8, 2012 -
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY),
announced today four-year follow-up data from patients enrolled in
the phase 2 clinical trial for its investigational oral therapy for
Gaucher disease type 1 known as eliglustat tartrate. Sustained or
further improvements were...
Read more... Posted Yesterday in Clinical Trials
Avanir Pharmaceuticals
Announces Publication of Phase III Study Results Showing Efficacy
and Safety of AVP-923 in the Treatment of Diabetic Neuropathic
Pain
ALISO VIEJO, Calif., Feb. 8,
2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ:
AVNR) announced today that the results of the study entitled
"Efficacy and Safety of Dextromethorphan/Quinidine (AVP-923) at Two
Dosage Levels for...
Read more... Posted Yesterday in Clinical Trials
NEW YORK & BUDAPEST, Hungary--(BUSINESS WIRE)--Feb 8, 2012 -
Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc. today
announced preliminary top-line results from a Phase III clinical
trial of cariprazine (RGH-188), an investigational antipsychotic
agent, in patients with acute mania associated with bipolar I
disorder.
For the primary endpoint, the Young Mania Rating Scale...
Read more... Posted Yesterday in Clinical Trials
Data previously presented at
ESPID annual meeting add to the body of evidence showing that
Bexsero can help protect all vulnerable age
groups
Study including more than 1,800
infants showed Bexsero induces robust immune response when given
alone or with other routine vaccines in different vaccination
schedules[1]
Current vaccines do not...
Read more... Posted 2 Days Ago in Clinical Trials
SEATTLE, Feb. 7, 2012 /PRNewswire/ -- Omeros Corporation
(NASDAQ: OMER) today announced that recent positive clinical
developments have allowed it to revise the planned analysis for its
ongoing Phase 3 clinical trial evaluating OMS302, which Omeros
believes expands opportunities for the product's clinical and
regulatory success. OMS302 is a proprietary combination of an
anti-inflammatory...
Read more... Posted 2 Days Ago in Clinical Trials
-- JX-594 Selectivity is Multi-Mechanistic, Driven by Genetic
Traits Common in Solid Tumors --
SAN FRANCISCO, Feb. 7, 2012 /PRNewswire/ -- Jennerex, Inc., a
private clinical-stage biotherapeutics company focused on the
development and commercialization of first-in-class targeted
oncolytic virus products for cancer, today announced the
publication in Molecular Therapy of data validating the...
Read more... Posted 2 Days Ago in Clinical Trials
DENVER--(BUSINESS WIRE)--Feb 7, 2012 - Cannabis Science, Inc.
(OTCBB:CBIS) a pioneering U.S. biotech company developing
pharmaceutical cannabis (marijuana) products, is pleased to present
the newest set of photographs showing evidence that the cancer
cells appear to have been killed over the course of treatment from
the 2nd self-administering cancer patient suffering from squamous
cell...
Read more... Posted 2 Days Ago in Clinical Trials
Preclinical Research Validates Role of BMP Pathway in
Treating Progressive Kidney Disease and Potential for Thrasos'
Compounds to Selectively Target the Pathway
MONTREAL--(BUSINESS WIRE)--Feb 7, 2012 - Thrasos today announced
that the journal Nature Medicine has published the results
of a collaborative research program detailing the role of the bone
morphogenic protein (BMP) pathway in the...
Read more... Posted 2 Days Ago in Clinical Trials
PALO ALTO, Calif.--(BUSINESS WIRE)--Feb 7, 2012 - Anacor
Pharmaceuticals (NASDAQ:ANAC) announced today positive preliminary
results from two safety studies of AN2728 - a maximal use systemic
exposure (MUSE) study in psoriatic patients and a local
tolerability study. The results of these two studies demonstrate
that AN2728 Ointment, 2% appears to be safe and well-tolerated when
applied to...
Read more... Posted 2 Days Ago in Clinical Trials
Phase III study met primary
endpoint
INDIANAPOLIS, Feb. 7, 2012
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today
that a Phase III study, published online by European Urology,
showed both Cialis® (tadalafil) and tamsulosin significantly
improved scores on the International Prostate Symptom Score (IPSS),
compared to placebo, in men with signs and symptoms suggestive...
Read more... Posted 2 Days Ago in Clinical Trials
Company Will Review Data FromTRA-2P and TRACER With External
Experts to Inform Next Steps
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Feb 7, 2012 - Merck
(NYSE:MRK), known outside the United States and Canada as MSD,
today announced the top-line results of the TRA-2P (Thrombin
Receptor Antagonist in Secondary
Prevention of atherothrombotic ischemic events) study of
vorapaxar. Merck is...
Read more... Posted 2 Days Ago in Clinical Trials
BERKELEY,
Calif.--(BUSINESS WIRE)--Feb
7, 2012 - Aduro BioTech, Inc. is pleased to announce the
publication of two therapeutic cancer vaccine Phase 1
studies in Clinical Cancer Research (volume 18(3),
pages 1-11). In the article, which was featured as one of the
highlights of the issue, Dr. Dung Le et al. reported that
intravenous administration of ANZ-100 and CRS-207 was well
tolerated...
Read more... Posted 3 Days Ago in Clinical Trials
Aim to File for Approval
of Lubiprostone as First Oral Drug for Prescription-based Treatment
of OBD
Anticipate sNDA Filing in US
in First Half of 2012
– Sucampo Pharmaceuticals, Inc.
(NASDAQ: SCMP) (SPI) and Takeda Pharmaceuticals U.S.A., Inc.
announced today that lubiprostone met the primary endpoint in a
phase 3 clinical trial for the treatment of opioid-induced bowel
dysfunction...
Read more... Posted 3 Days Ago in Clinical Trials
Paris, February 2,
2012
- The New England Journal of Medicine
(NEJM) today published results of two phase III clinical trials
introducing ulipristal acetate, HRA Pharma proprietary compound, as
an effective pre-operative treatment of symptoms of uterine
fibroids.
According to data published
in NEJM from two pivotal clinical trials, PEARL I and PEARL II,
treatment with ulipristal...
Read more... Posted 3 Days Ago in Clinical Trials
QUÉBEC
CITY, Feb. 3, 2012 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:
AEZS) (TSX:?AEZ) (the "Company") today reported positive updated
results for the Phase 1 portion of its ongoing Phase 1/2 study in
castration- and taxane-resistant prostate cancer (CRPC) with
AEZS-108 (zoptarelin doxorubicin), the Company's targeted cytotoxic
luteinizing hormone-releasing hormone (LHRH) analog. Data...
Read more... Posted 3 Days Ago in Clinical Trials
DETROIT, Feb. 6, 2012 – A Henry Ford Hospital study has
found that using two types of common asthma medications in
combination reduces severe asthma attacks.
Researchers say using long-acting beta-agonists (LABAs) in
fixed-dose combination with inhaled corticosteroid (ICS) appear to
reduce asthma attacks as well as or better than corticosteroids
alone. Patient groups who had in...
Read more... Posted 3 Days Ago in Clinical Trials
Remedy Pharmaceutical's drug may finally hold the answer to
solving this medical dilemma
NEW YORK--(BUSINESS WIRE)--Feb 6, 2012 - Each year, over 700,000
people in the United States suffer a stroke. For most, medical
science can do very little. Some will die; a number will suffer
debilitating aftereffects. Now, preliminary results of a Phase 2
clinical trial using Remedy Pharmaceuticals'...
Read more... Posted 3 Days Ago in Clinical Trials
-Results Support Planned, Randomized Phase 3 ADAPT Study-
DURHAM, N.C., Feb. 4, 2012 /PRNewswire/ -- Argos Therapeutics
Inc. today announced that updated results from an open label
Phase 2 study of its Arcelis
immunotherapy, AGS-003, in combination with sunitinib in patients
with unfavorable risk, metastatic renal cell carcinoma (mRCC), had
demonstrated prolonged survival. Based...
Read more...
